Skip to main content
letter
. 2020 Feb 20;79(6):842–844. doi: 10.1136/annrheumdis-2019-216699

Figure 1.

Figure 1

Contribution of improving systemic inflammation and sparing glucocorticoid dose with tofacitinib therapy. (A) Changes in systemic score in adult-onset Still’s disease patients from baseline. (B–F) White cell count (WBC) count, neutrophil per cent, erythrocyte sedimentation rate (ESR), CRP levels and ferritin levels from baseline. (G) Glucocorticoid-sparing effects of tofacitinib administration. All data were statistically analysed using SPSS V.23.0. *p<0.05, **p<0.01, ***p<0.001.